Today, hundreds of thousands of patients worldwide with autoimmune diseases, including psoriasis, are treated with anti-inflammatory cytokines that inhibit IL-1, although a small percentage of those treated may develop bacterial infections. This evidence concerns the gene IL1B and autoimmune disease.